VerImmune Inc Announces Upcoming Oral and Poster Presentations at the 35th IPV and AACR Annual meeting 2023

VerImmune, Inc. (“VerImmune”), an innovative biotechnology company leading the way in developing virus-inspired particle modalities for cancer treatment is proud to announce the publication of scientific abstracts for an upcoming Oral presentation at the 35th International Papillomavirus Conference taking place April 17-21 in Washington DC as well as a Poster presentation at the American Associate for Cancer Research Annual 2023 Meeting, taking place April 14-19 in Orlando, Florida.

 

Details for the Oral and Poster presentations are as follows:

American Associate for Cancer Research (AACR) Annual Meeting

Published Abstract Number: 1854

Title: CANCER TREATMENT UTILIZING VIRUS-INSPIRED PARTICLES FOR THE REDIRECTION OF IMMUNE MEMORY

Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 2
Session Date and Time: Monday Apr 17, 2023 9:00 AM - 12:30 PM
Location: Poster Section 24
Poster Board Number: 26

35th International Papillomavirus Conference

Title: REDIRECTING PRE-EXISTING VIRAL IMMUNITY TOWARDS CANCERS VIA MURINE PAPILLOMAVIRUS T=1 VIRUS-INSPIRED PARTICLES (VIPS)

Session Name: BASIC SCIENCE ORAL: IMMUNOLOGY & VACCINES
Session Type: Basic Science Oral Abstracts Session
Session Date and time: April 21st 2023;  08:00 - 09:30
Location Room 207A

 

About VerImmune
VerImmune is a biotechnology company developing a novel first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) technology platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or experience cancer treatment resistance. For more information, visit http://www.verimmune.com

joshua wang